MCGRATH JOHN 4
4 · Atara Biotherapeutics, Inc. · Filed Mar 20, 2018
Insider Transaction Report
Form 4
MCGRATH JOHN
Chief Financial Officer
Transactions
- Sale
Common Stock
2018-03-19$41.99/sh−3,000$125,970→ 91,762 total - Sale
Common Stock
2018-03-20$38.83/sh−3,000$116,490→ 88,762 total
Footnotes (3)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.